Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

Group 1: Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on discovering and developing proprietary drugs for cancer treatment, utilizing its Phospholipid Drug Conjugate™ (PDC) delivery platform to enhance efficacy and safety [3][4]. - The company's product pipeline includes its lead asset, iopofosine I 131, designed for targeted delivery of iodine-131, along with other preclinical PDC chemotherapeutic programs and partnered assets [3]. Group 2: Industry Context - Waldenstrom's macroglobulinemia is a B-cell malignancy with approximately 26,000 prevalent cases in the US, with 1,500-1,900 new diagnoses annually [2]. - There is a significant unmet need for new FDA-approved treatments for patients with Waldenstrom's macroglobulinemia, particularly those who have progressed on BTKi therapy, as current options do not provide complete response rates and require continuous treatment [2]. - Approximately 50% of third-line patients not receiving treatment are likely to consider new treatment options, indicating a demand for innovative therapies that offer novel mechanisms of action and improved patient outcomes [2]. Group 3: Upcoming Events - Cellectar Biosciences will host an event on July 24, 2024, at 8:00 a.m. EDT to discuss recent data from its pivotal trial of iopofosine I 131 in Waldenstrom's macroglobulinemia, the current treatment landscape, and opportunities to improve patient outcomes [4][5].